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SUMMARY
We studied changes in species distribution and antimicrobial resistance patterns of Shigella
during 1980–2008, using the Diarrhoeal Diseases Surveillance system of Dhaka Hospital
of ICDDR,B. In hospitalized patients Shigella prevalence decreased steadily from 8–12% in the
1980s to 3% in 2008. Endemic S. ﬂexneri was the most commonly isolated species (54%).
Epidemic S. dysenteriae type 1 had two peaks in 1984 and 1993, but was not found after 2000,
except for one case in 2004. The therapeutic options are now limited: in 2008 a total of 33%
of S. ﬂexneri were resistant to ciproﬂoxacin and 57% to mecillinam. In the<5 years age group,
severely underweight, wasted and stunted children were more at risk of shigellosis compared
to well-nourished children (P<0.001). Although hospitalization for Shigella diarrhoea is
decreasing, the high levels of antimicrobial resistance and increased susceptibility of malnourished
children continue to pose an ongoing risk.
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INTRODUCTION
Of the estimated 165 million annual episodes of
shigellosis worldwide, 99% occur in low-income
countries, largely in children aged <5 years, who
represent 69% of the episodes and 60% of deaths [1].
A population-based study conducted in one urban
slum of Bangladesh observed an incidence of shi-
gellosis of 7.9/1000 person-years, but the rate was
60% higher (13.2/1000 person years) in children aged
<5 years [2]. Childhood malnutrition is a major pub-
lic health problem in Bangladesh, where >40% of
pre-schoolchildren are malnourished [3] ; these chil-
dren are not only at higher risk of Shigella infections,
but also experience complications and fatal outcomes
more often [4, 5]. Disease severity and outcome diﬀer
substantially for the four species of Shigella (S. dys-
enteriae, S. ﬂexneri, S. boydii, S. sonnei) : S. dysenter-
iae type 1(Sd1) outbreaks or epidemics are associated
with higher rates of complications and deaths. In
Bangladesh the majority of deaths due to endemic
shigellosis were associated with S. ﬂexneri [5, 6].
* Author for correspondence : F. Khatun, MBBS, M.Sc., Public
Health Sciences Division, ICDDR,B, 68 Shaheed Tajuddin Ahmed
Sarani, Mohakhali, Dhaka-1212, Bangladesh.
(Email : kfatema@icddrb.org)
Epidemiol. Infect. (2011), 139, 446–452. f Cambridge University Press 2010
doi:10.1017/S0950268810001093
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0950268810001093
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 14:45:12, subject to the Cambridge Core terms of use, available at
Distribution of serotype diﬀers between industrial-
ized and developing countries. Serotype distribution
changed in Thailand as the country’s economy devel-
oped [7]. Heterogeneous distribution of Shigella spp.
and serotype have been observed in surveillance con-
ducted in six Asian countries [2].
In Bangladesh, from 1968 to 1979, hospital-based
studies conducted at urban Dhaka Hospital and rural
Matlab Hospital of ICDDR,B observed that S. ﬂex-
neri was the most predominant strain, with one Sd1
epidemic in 1973. The ﬁrst documented outbreak of
Sd1 in Bangladesh occurred in St Martin’s Island,
a coral island in the Bay of Bengal, from May to July
1973. Of 434 recognized cases 28 (6.4%) died, mostly
infants and elderly people [8]. At that time, all strains
of Shigella were found to be susceptible to most of
the conventional antimicrobials used in Bangladesh,
including tetracycline and chloramphenicol.
The prevalence of diﬀerent species of Shigella and
their antimicrobial susceptibility change over time,
making treatment diﬃcult [9]. Therefore, regular
monitoring of species distribution and antimicrobial
susceptibility is important, both for case management
of individual patients, especially those at higher
risk such as severely malnourished children aged
<5 years, and for epidemic preparedness.
In this paper we aimed to describe the changing
trend and antimicrobial susceptibility pattern of shi-
gellosis by analysing the database of the Diarrhoeal
Disease Surveillance system of ICDDR,B from 1980
to 2008.
METHODS
The Dhaka Hospital of ICDDR,B is located in the
capital city of Bangladesh, Dhaka, and it provides
care and treatment to about 100 000 patients each
year, mostly residents of the city and its peri-urban
areas, while a smaller proportion come from outside
the city and even from distant parts of the country.
The hospital has maintained a Diarrhoeal Disease
Surveillance system since late 1979, enrolling a sys-
tematic 2% sample of all patients attending this
facility. The system collects information on the clini-
cal, epidemiological and demographic characteristics
of every 50th patient, irrespective of age, sex or socio-
economic status. In determining this sample frame,
it was assumed that the system should be able to
detect a signiﬁcant diﬀerence (P<0.05, two-sided) in
the isolation of speciﬁc enteropathogens when cases
were compared with controls (e.g. isolation rate of
5.8% in cases and 2.5% in controls), requiring an
annual sample size of 660 cases and 660 controls. To
facilitate subgroup analysis it was estimated that a
sample size of 2000 would be adequate. A systematic
sample of 2% would provide at least 2000 patients
from a total of over 100 000 patients attending the
hospital.
Trained research assistants interviewed patients, or
the guardian of minors, using a structured question-
naire. A physician performed physical examinations
at the time of hospitalization and recorded the ﬁnd-
ings. For this analysis we extracted data from January
1980 to December 2008, and reviewed patients with
culture-positive Shigella infections.
For laboratory conﬁrmation of Shigella, freshly
collected stool specimens were immediately sent to
the laboratory where they were inoculated onto
MacConkey (MAC) and Salmonella–Shigella (SS)
agar media plates. Shigella spp. were isolated and
identiﬁed using standard laboratory methods [10],
and the species and their serotype were conﬁrmed
using commercial antisera kits (Denka Seiken, Japan)
speciﬁc for polyvalent and monovalent antigens
for all serovars. The same culture method was used
during the entire study period. Antimicrobial suscep-
tibility of the isolated strains was determined by the
disc diﬀusion method as recommended by the Clinical
Laboratory and Standard Institute, CLSI [formerly
the National Committee for Clinical Laboratory
Standards (NCCLS)] [11]. The antibiotic discs used
in this study (Oxoid, UK) included ampicillin
(10 mg), mecillinam (25 mg), nalidixic acid (30 mg),
trimethoprim–sulphamethoxazole (T-S) (25 mg), and
ciproﬂoxacin (5 mg). Escherichia coli ATCC 25922
was used as the control strain for susceptibility
studies [11].
x2 was used for assessing trends, and Pf0.05 con-
sidered as signiﬁcant. For children aged <5 years,
we analysed the risk of Shigella infection between
malnourished and well-nourished children by calcu-
lating risk ratios (RR) and their 95% conﬁdence
intervals (CI).
Severe malnutrition was deﬁned as (all values
are z scores) : height-for-age <x3; weight-for-age
<x3, and weight-for-height <x3; using the World
Health Organization reference value [12]. Moderate
malnutrition was deﬁned as: height-for-age x3 to
>x2, weight-for-age x3 to >x2, and weight-for-
height x3 to >x2. We considered children as well
nourished if their weight-for-age, height-for-age and
weight-for-height werex2 or more.
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RESULTS
In total, 83 073 patients were enrolled in the Diar-
rhoeal Disease Surveillance system at the Dhaka
Hospital of ICDDR,B between 1980 and 2008.
The stool/rectal swab cultures of 7575 (9.1%) were
positive for Shigella. Of all patients infected with
Shigella, 3648 (49%) were aged<5 years, 961 (13%)
were aged 5–14 years, and 2891 (39%) were aged
o15 years. The age distribution remained stable over
time.
Of all Shigella strains, 55% were S. ﬂexneri, 19%
were S. dysenteriae, and 13% S. boydii (Table 1). The
overall yearly isolation rates of Shigella ranged be-
tween 8% and 12% during 1980–1995 (Fig. 1) and
then gradually decreased to 3% in 2008 (x2 for trend
P<0.001), except for a single year peak of 8% in
2000.
Two peaks of isolation of Sd1 occurred in 1984
and 1993 (Fig. 2), and then the isolation gradually
declined. This serotype was not isolated after 2000,
except for a single patient in 2004.
S. ﬂexneri remained the most prevalent strain
during the entire period of observation, except during
the peak of Sd1 epidemics in 1984 and 1993 when the
proportion of isolation of S. ﬂexneri and S. dysenter-
iae were almost identical (Fig. 2). In both these epi-
demics, the strains of Sd1 had acquired resistance
to newer antimicrobials, including tetracycline, T-S,
and ampicillin in 1984, and nalidixic acid in 1993.
In contrast, the development of resistance of S. ﬂex-
neri to ampicillin, and T-S has been much slower.
Similarly, resistance to nalidixic acid from 1986 to
1997 was a slow process, followed by a sharp rise from
1998 and reaching 60% in 2002. Since 2007 S. ﬂexneri
has begun to show resistance to ciproﬂoxacin and
mecillinam and by 2008, 33% of S. ﬂexneri was re-
sistant to ciproﬂoxacin and 56% to mecillinam. Other
strains of Shigella such as S. sonnei, S. boydii and
Shigella spp. together had a 12% resistance to
mecillinam and 9% to ciproﬂoxacin in 2008.
Of Shigella-positive children aged <5 years, 9%
were severely underweight, 10% severely wasted and
8% severely stunted, while only 5% of well-nourished
children aged <5 years were Shigella positive.
Compared to well-nourished children severely mal-
nourished children were at greater risk of developing
Shigella infection: severely underweight (RR 1.8,
P<0.001); severe wasting (RR 2.1, P<0.001) and
severe stunting (RR 1.7, P<0.001) (Table 2). The
proportion of malnourished children aged <5 years
with all aetiologies of diarrhoea has decreased over
time from 14% in severely underweight in 1993 to 4%
in 2008. Similarly stunting was 11% in 1993 and 4%
in 2008 (data not shown).
DISCUSSION
At the Dhaka Hospital of ICDDR,B the proportions
of patients admitted with shigellosis decreased over
time from 12% in 1980 to 3% in 2008. A moderate
reduction in the estimated number of Shigella infec-
tions and a large reduction of mortality have been
reported by a literature review in Asia [13]. Similar
reductions in developed countries have been at-
tributed to improvements in safe water supply, ad-
equate sanitation facilities, and maintenance of good
personal hygiene [14]. We do not have a deﬁnitive
explanation for the reduction in shigellosis in
Bangladesh from our study, but higher rates of iso-
lation of Shigella from severely malnourished children
and the reductions in the proportions of severely
malnourished children in Bangladesh in recent years,
would suggest that improved nutrition could be a
likely factor. The association between measles and
shigellosis, including higher severity and deaths from
these two conditions co-occurring is well docu-
mented; in Bangladesh the immunization coverage
against measles was 70% in 1996 and 83% in 2007
[3, 15]. Vitamin A is an important factor in preventing
infectious illnesses. The coverage of vitamin A capsule
supplementation in children increased from 40%
in 1995 to around 70% in 2003 [16]. An earlier study
conducted at ICDDR,B demonstrated the therapeutic
beneﬁts of vitamin A supplementation when used
as an adjunct to antimicrobial therapy [17]. Although
vitamin A was used in case management of shigellosis,
Table 1. Proportion of Shigella species distribution
1980–2008, Dhaka Hospital Surveillance system,
ICDDR,B
Species
No. of
isolates
Proportion (%)
of Shigella spp.,
median (IQR)
Shigella ﬂexneri 4157 55 (46–63)
Shigella dysenteriae 1 1457 17 (0–25)
Shigella boydii 1002 14 (10–21)
Shigella sonnei 458 7 (4–9)
Shigella spp. 501 4 (2–6)
IQR, Interquartile range.
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not as a preventive strategy, it seems reasonable to
consider improved vitamin A status as a factor that
might have contributed to reducing the prevalence of
shigellosis in Bangladesh.
In Bangladesh, all four species of Shigella are
present. S. ﬂexneri is the most prevalent endemic
species, and Sd1 has caused two epidemics since
1980 (in 1984 and 1993) but has not been isolated
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Fig. 1. Isolation rate (%) of Shigella between 1980 and 2008. Dhaka Hospital Surveillance system, ICDDR,B.
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Fig. 2. Total numbers of Shigella dysenteriae type 1 ( ) and Shigella ﬂexneri (%), 1980–2008. Dhaka Hospital Surveillance
system, ICDDR,B.
Table 2. Nutritional risk factor for shigellosis in children aged<5 years from 1993 to 2008, Dhaka Hospital
Surveillance system, ICDDR,B
Number (%) of
children aged
<5 years in respective
nutritional category
(n=19 511)
Number (%) of
children in this
nutritional category
with Shigella
(n=1193)
Risk ratio*
(95% CI) P
Moderately underweight 5389 (27.6) 345 (6.4) 1.3 (1.2–1.5) <0.001
Severely underweight 3566 (18.2) 312 (8.7) 1.8 (1.6–2.1) <0.001
Moderate wasting 3231 (16.5) 261 (8.1) 1.7 (1.4–2.0) <0.001
Severe wasting 712 (3.6) 71 (10.0) 2.1 (1.6–2.6) <0.001
Moderate stunting 3878 (19.9) 252 (6.5) 1.4 (1.2–1.6) <0.001
Severe stunting 2515 (12.9) 210 (8.3) 1.7 (1.5–2.0) <0.001
Well nourished 8367 (42.9) 403 (4.8) —
* All groups are compared to the well-nourished group.
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since 2001 (Fig. 2). Hospital-based surveillance is
not usually representative of an epidemic, yet in
Bangladesh there were no population-based studies
until 2001, so we considered the results of our
hospital-based surveillance as a proxy indicator
for these two epidemics [18, 19]. Both of these Sd1
epidemics were caused by strains that had acquired
resistance to the antimicrobial agents in routine use
for treating shigellosis. Of all the species of Shigella,
the emergence of resistance and its quick progression
is most notable in Sd1 strains.
After these two epidemics, separated by a decade-
long interval, Shigella experts anticipated another
epidemic in 2004 [20]. The factors underlying this
trend of periodic epidemics have not been explored.
Our data show that resistance to Sd1 is stable and
has acquired resistance to additional antimicrobials,
leading to a situation with limited options for em-
pirical antimicrobial therapy. Despite ﬂuctuations in
the rates of isolation of Sd1, the serotype was isolated
in all the years of our study period, except for 2001 to
2008, but in 2004 it was isolated from a single patient
at Dhaka Hospital. The only other record was an
outbreak of ciproﬂoxacin-resistant Sd1 in northeast
Bangladesh associated with an 8% case-fatality rate
in late 2003 [21]. The reason behind the apparent dis-
appearance of Sd1 from Bangladesh is not known,
but Sd1 has returned after long dormant intervals,
with resistance to additional antimicrobials, in both
eastern India and Malaysia [22, 23].
Although not as rapid as Sd1, the growing resist-
ance since 2007 inS.ﬂexneri, particularly against cipro-
ﬂoxacin and mecillinam (the WHO recommended
ﬁrst- and second-line treatment of shigellosis), is also
a matter of concern. Resistance to quinolones is as-
sociated with chromosomal mutation in Shigella, or
transfer of resistance factors from other co-inhibiting
microbes that are resistant to the ﬂuroquinolones
[24, 25]. The development of resistance to nalidixic
acid, an older quinolone, raised concerns that resist-
ance would also emerge against ciproﬂoxacin. Our
data demonstrated that to be the case. Second-line
drugs are azithromycin and ceftriaxone. Azithro-
mycin has been tested and proved to be eﬀective in
adults, and is less costly and easier to use compared to
parenteral ceftriaxone [26]. Although not evaluated in
the treatment of shigellosis in children, there is no
reason to believe that this drug will not be eﬀective in
children.
The rate of childhood malnutrition remains high
in Bangladesh, despite a reduction from 56% of
children aged <5 years in 1990 to 45% in 2005 [27].
Compared to better nourished children, the preva-
lence of Shigella in our study was higher in under-
weight, stunted, and wasted children aged <5 years,
which is similar to earlier observations [5]. Of all
diarrhoeal diseases, the negative nutritional impact is
greater with shigellosis, due to presence of fever,
greater anorexia, and the loss of enteric proteins, and
has been associated with decreased linear growth rate
in previous studies in Bangladesh [4, 28].
Our dataset is hospital based, which might not
represent the population at large, with a possible bias
towards children with more severe disease and those
who fail outpatient treatment. Thus, the prevalence
of antimicrobial resistance may be less in the com-
munity. Over time, the number of hospital admissions
increased because the population of Dhaka city has
grown and referral mechanism towards ICDDR,B
Dhaka hospital has improved. We performed sys-
tematic sampling and presented the proportion of
Shigella infection, thus increased hospital admission
did not aﬀect our results.
Urban populations in Bangladesh have better ac-
cess to healthcare facilities, including those services
received from public and private clinics/hospitals,
general practitioners, which could have been a factor
for our observation of reducing prevalence of shi-
gellosis. The availability of highly potent drugs, such
as ciproﬂoxacin, that are available over the counter
could also have contributed [29]. The prevalence of
shigellosis in Kamlapur, an urban ﬁeld area of
ICDDR,B is higher than that observed in our study
with an isolation rate of 13% between 2002 and 2004
[2]. In addition, isolation rates of Shigella were
higher in rural Matlab Hospital of ICDDR,B and
another rural community-based study in Mirzapur
(Dr A. S. G. Faruque, personal communication;
Matlab and Mirzapur surveillance data). A nation-
wide Shigella surveillance could provide a more com-
plete estimate of Shigella prevalence.
Shigellosis is one of the few diarrhoeal diseases for
which the WHO recommends routine antimicrobial
therapy, using an eﬀective agent to reduce morbidity,
complications and deaths. It seems that Sd1, the
serotype of Shigella that causes the most severe illness
with greater complications and deaths and is the most
eﬃcient in acquiring resistance to antimicrobials, has
disappeared from Bangladesh, at least temporarily.
However, the rapid emergence of resistance of other
Shigella strains, especially S. ﬂexneri, the most preva-
lent endemic species, is a matter of concern. The
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recent resistance to ciproﬂoxacin and mecillinam has
left only azithromycin and ceftriaxone as drugs with
proven eﬃcacy in the management of shigellosis.
However, ceftriaxone is only available in parenteral
formulation that requires hospitalization in health-
care facilities. It is also expensive, making it inaccess-
ible, particularly to families of severely malnourished
children of low socioeconomic status. Severely mal-
nourished children are not only at a greater risk
of shigellosis, but are also at greater risk of related
complications and deaths.
Our data highlight the importance of hospital-
based surveillance in understanding the changing
epidemiology of Shigella infections, including changes
in antimicrobial susceptibility that would be helpful
in the case management of shigellosis. Although the
proportion of patients hospitalized for shigellosis
has decreased over the last 28 years, the increase
in antimicrobial resistance, the continued suscepti-
bility of malnourished children to Shigella, and the
history of prior Sd1 outbreaks means that Shigella
represents an ongoing threat to public health in
Bangladesh.
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